This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Amgen (AMGN) Q3 Earnings Top Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 6.67% and 0.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $57.44 in the latest trading session, marking a +0.23% move from the prior day.
ANI Pharmaceuticals (ANIP) Stock Moves -0.14%: What You Should Know
by Zacks Equity Research
The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $57.31, representing a -0.14% change from its previous close.
ANI Pharmaceuticals (ANIP) Stock Moves -0.48%: What You Should Know
by Zacks Equity Research
In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $57.66, indicating a -0.48% shift from the previous trading day.
ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw ANI Pharmaceuticals (ANIP) settling at $58.39, representing a -0.41% change from its previous close.
(ANIP) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, ANI Pharmaceuticals (ANIP) closed at $58.63, indicating a +1.98% shift from the previous trading day.
ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $58.06 in the latest trading session, marking a -1.41% move from the prior day.
Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed the most recent trading day at $59.33, moving -1.98% from the previous trading session.
ANI Pharmaceuticals (ANIP) Stock Moves -0.9%: What You Should Know
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) closed at $60.53 in the latest trading session, marking a -0.9% move from the prior day.
Elutias (ELUT) Up on Sale of Orthobiologics Business for $35M
by Zacks Equity Research
Elutias (ELUT) gains on divestiture of Orthobiologics business unit for $35 million to Berkeley Biologics LLC, a wholly-owned subsidiary of GNI Group Ltd.
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion for DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy.
ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $63.61, marking a +1.26% move from the previous day.
UnitedHealth Group (UNH) Wins Medicaid Deal to Help Serve Texas
by Zacks Equity Research
UnitedHealth Group (UNH) unit has been awarded a contract by the Texas Health and Human Services Commission to better cater to the statewide Medicaid members.
Here's Why You Should Add ANI Pharmaceuticals (ANIP) to Your Portfolio
by Zacks Equity Research
ANI Pharmaceuticals (ANIP), a top-ranked stock, has a diverse portfolio of rare disease and generic medicines. Its Purified Cortrophin Gel is witnessing incremental sales in recent quarters.
ANI (ANIP) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study
by Zacks Equity Research
Lisata's (LSTA) shares gain on a favorable outcome in interim futility analysis of its lead candidate, LSTA1, for pancreatic cancer.
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
by Zacks Equity Research
Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies.
Ensign Group (ENSG) Pursues Facility Buyouts in South Carolina
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in South Carolina to offer enhanced healthcare services to the state's residents.
Insmed (INSM) Up on Positive Data From MAC Lung Disease Study
by Zacks Equity Research
Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.
InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why
by Zacks Equity Research
Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.
Sage Therapeutics (SAGE) Plunges 46% in a Month: Here's Why
by Zacks Equity Research
The plunge in Sage's (SAGE) shares comes after the FDA declined to approve Zurzuvae in major depressive disorder indication, citing management to conduct more clinical studies.
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
by Zacks Equity Research
Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.
Humana (HUM) to Provide In-home Care With Primary Care Anywhere
by Zacks Equity Research
Humana (HUM) enhances its CenterWell brand with the launch of Primary Care Anywhere.